Foslevodopa is a phosphate prodrug of levodopa developed to improve the delivery of levodopa for the treatment of Parkinson's disease. It is converted to levodopa in the body and is used in combination with foscarbidopa for continuous subcutaneous administration in patients with advanced Parkinson's disease.
Foslevodopa is a specialized pharmaceutical active ingredient belonging to the antiparkinsonian drug class. It is a water-soluble phosphate ester prodrug of levodopa and is designed for continuous delivery through subcutaneous infusion.
CAS Number: 85821-19-8
Molecular Formula: C9H12NO6P
Molecular Weight: 261.17 g/mol
Drug Class: Antiparkinsonian Agent
Chemical Class: Phosphate Prodrug of Levodopa
Active Drug: Levodopa
Therapeutic Area: Neurology / Parkinson's Disease
Foslevodopa is converted to levodopa after administration. Levodopa crosses the blood-brain barrier and is subsequently converted to dopamine in the brain. Increasing dopamine availability in the striatum helps compensate for the dopamine deficiency associated with Parkinson's disease and improves motor symptoms.
Foslevodopa is used as part of continuous dopaminergic therapy for patients with advanced Parkinson's disease who experience motor fluctuations despite conventional oral levodopa treatment. The pharmaceutical combination of foslevodopa and foscarbidopa provides continuous subcutaneous delivery of levodopa and carbidopa.
Foslevodopa is formulated together with foscarbidopa, the phosphate prodrug of carbidopa. Foscarbidopa inhibits peripheral conversion of levodopa to dopamine, allowing more levodopa to reach the brain. The combination is administered by continuous subcutaneous infusion.
Foslevodopa is a phosphate-containing levodopa prodrug designed to provide substantially improved aqueous solubility compared with levodopa. Its phosphate ester structure enables formulation at concentrations suitable for continuous subcutaneous administration.
Foslevodopa API quality assessment can include identification, assay, related substances, water content, residual solvents, elemental impurities and other appropriate pharmaceutical quality-control tests. HPLC and other validated analytical techniques may be used for assay and impurity determination.
Foslevodopa should be stored in accordance with the applicable pharmaceutical specification and validated stability conditions. The material should be protected from unsuitable temperature, moisture and light conditions and handled according to appropriate pharmaceutical procedures.
Foslevodopa represents a prodrug-based approach to improving the pharmaceutical delivery of levodopa. Its increased aqueous solubility supports concentrated aqueous formulations for continuous subcutaneous administration, providing an alternative to intermittent oral dosing in advanced Parkinson's disease.
Foslevodopa is a phosphate prodrug of levodopa developed for continuous subcutaneous dopaminergic therapy. It has the CAS Number 85821-19-8, molecular formula C9H12NO6P, and molecular weight 261.17 g/mol. It is used together with foscarbidopa for continuous treatment of motor fluctuations in adults with advanced Parkinson's disease.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 1.0% |
| pH (1% Solution) | 5.0 – 7.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 2.0% |